Yesterday, Aug. 26, 2015, 121 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $95.86 to $14,679,317.76.

Highlighted Stocks Traded by Insiders:

SolarWinds (SWI) - FREE Research Report

Ream Jason, who is Evp & Cfo at SolarWinds, sold 1,875 shares at $37.65 on Aug. 26, 2015. Following this transaction, the Evp & Cfo owned 73,879 shares meaning that the stake was reduced by 2.48% with the 1,875-share transaction.

The shares most recently traded at $40.61, up $2.96, or 7.29% since the insider transaction. Historical insider transactions for SolarWinds go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 5,850
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 32,452
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 32,452

The average volume for SolarWinds has been 1.2 million shares per day over the past 30 days. SolarWinds has a market cap of $3.0 billion and is part of the technology sector and computer software & services industry. Shares are down 19.39% year-to-date as of the close of trading on Wednesday.

SolarWinds, Inc., together with its subsidiaries, designs, develops, markets, sells, and supports enterprise-class information technology (IT) and infrastructure management software to IT and DevOps professionals in various organizations worldwide. The company has a P/E ratio of 34.3. Currently, there are 5 analysts who rate SolarWinds a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SWI - FREE

TheStreet Quant Ratings rates SolarWinds as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures and compelling growth in net income. However, as a counter to these strengths, we also find weaknesses including a generally disappointing performance in the stock itself and disappointing return on equity. Get the full SolarWinds Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Celldex Therapeutics (CLDX) - FREE Research Report

Ellberger Larry, who is Director at Celldex Therapeutics, bought 5,000 shares at $14.00 on Aug. 26, 2015. Following this transaction, the Director owned 53,500 shares meaning that the stake was boosted by 10.31% with the 5,000-share transaction.

The shares most recently traded at $14.88, up $0.88, or 5.91% since the insider transaction. Historical insider transactions for Celldex Therapeutics go as follows:

  • 4-Week # shares bought: 20,800
  • 12-Week # shares bought: 20,800
  • 24-Week # shares bought: 20,800

The average volume for Celldex Therapeutics has been 1.6 million shares per day over the past 30 days. Celldex Therapeutics has a market cap of $1.4 billion and is part of the health care sector and drugs industry. Shares are down 21.32% year-to-date as of the close of trading on Wednesday.

Celldex Therapeutics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes novel therapeutics for human health care in the United States. Currently, there are 8 analysts who rate Celldex Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CLDX - FREE

TheStreet Quant Ratings rates Celldex Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, weak operating cash flow, feeble growth in its earnings per share and generally disappointing historical performance in the stock itself. Get the full Celldex Therapeutics Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

CoreLogic (CLGX) - FREE Research Report

Folino Paul F, who is Chairman at CoreLogic, sold 3,200 shares at $36.66 on Aug. 26, 2015. Following this transaction, the Chairman owned 10,712 shares meaning that the stake was reduced by 23% with the 3,200-share transaction.

The shares most recently traded at $37.54, up $0.88, or 2.36% since the insider transaction. Historical insider transactions for CoreLogic go as follows:

  • 4-Week # shares bought: 1,605
  • 4-Week # shares sold: 1,600
  • 12-Week # shares bought: 1,605
  • 12-Week # shares sold: 16,600
  • 24-Week # shares bought: 1,605
  • 24-Week # shares sold: 43,600

The average volume for CoreLogic has been 707,900 shares per day over the past 30 days. CoreLogic has a market cap of $3.2 billion and is part of the technology sector and telecommunications industry. Shares are up 17.92% year-to-date as of the close of trading on Wednesday.

CoreLogic, Inc. provides property information, analytics, and data-enabled services in North America, Western Europe, and the Asia Pacific. The company operates through two segments, Technology and Processing Solutions and Data & Analytics (D&A). The company has a P/E ratio of 25.9. Currently, there are 7 analysts who rate CoreLogic a buy, 1 analyst rates it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CLGX - FREE

TheStreet Quant Ratings rates CoreLogic as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, reasonable valuation levels, compelling growth in net income, expanding profit margins and solid stock price performance. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full CoreLogic Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.